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Osteoclasts are multinucleated cells with bone resorption activity that is crucial for bone remodeling.
RANK‐RANKL (receptor activator of nuclear factor κB ligand) signaling has been shown as a main signal
pathway for osteoclast differentiation. However, the molecular mechanism and the factors regulating
osteoclastogenesis remain to be fully understood. In this study, we performed a chemical genetic screen,
and identiﬁed a Cdks/GSK-3β (cyclin-dependent kinases/glycogen synthase kinase 3β) inhibitor, ken-
paullone, and two Cdks inhibitors, olomoucine and roscovitine, all of which signiﬁcantly enhance os-
teoclastogenesis of RAW264.7 cells by upregulating NFATc1 (nuclear factor of activated T cells, cyto-
plasmic 1) levels. We also determined that the all three compounds increase the number of osteoclast
differentiated from murine bone marrow cells. Furthermore, the three inhibitors, especially kenpaullone,
promoted maturation of cathepsin K, suggesting that the resorption activity of the resultant osteoclasts is
also activated. Our ﬁndings indicate that inhibition of GSK-3β and/or Cdks enhance osteoclastogenesis by
modulating the RANK–RANKL signaling pathway.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bone homeostasis is tightly controlled by osteoblasts and os-
teoclasts which are involved in bone formation and resorption,
respectively [1–3]. The imbalance between bone formation and
resorption leads to impaired bone remodeling and development of
bone disorders. Enhanced bone resorption by osteoclasts weakens
bone structure and can cause osteoporosis over time whereas
defects in the function of osteoclasts lead to osteopetrosis [1].
Osteoclasts are giant multinucleated cells derived from monocyte/
macrophage lineage precursor cells through the differentiation
process primarily induced by two cytokines, macrophage colony-
stimulating factor (M-CSF) and receptor activator of nuclear factor
κB ligand (RANKL), which are produced by osteoblasts [4]. The
M-CSF supports proliferation and survival of osteoclast precursor
cells, and upregulates RANK expression. The RANKL and RANK
interaction recruits adaptor protein TRAF6, which in turnB.V. This is an open access article u
akihara).
.assembles with TAB2-TAK1 to activate mitogen-activated kinases
(MAPKs) such as extracellular signal-regulated kinase (ERK), Jun
N-terminal kinase (JNK), and p38 as well as NF-κB pathways [5].
NF-κB is required for initial induction of NFATc1, a key transcrip-
tion factor for osteoclast differentiation. Then, MAPKs activate AP-
1 (c-Fos/c-Jun), that further ampliﬁes NFATc1 [6]. The activity of
NFATc1 is regulated by calcium signaling that is induced by acti-
vation of the immunoglobulin-like receptors associated with the
immunoreceptor tyrosine-based activation motif (ITAM)-harbor-
ing adaptor proteins, including DAP12 and FcRγ [7]. The activated
calcineurin dephosphorylates NFATc1, which subsequently trans-
locates to nucleus and cooperatively induces osteoclast-related
genes with other transcription factors such as MITF, PU.1, CREB,
and AP-1 [8]. Thus, the RANK–RANKL signaling activates various
downstream signaling pathways required for the osteoclastogen-
esis [9]. Recent studies have signiﬁcantly advanced our knowledge
about the regulatory mechanism of osteoclastogenesis pathway,
but the whole osteoclastic signaling network is yet unknown.
Therefore, we performed a chemical genetic screen to identify
novel pathways and factors which controls osteoclastogenesis by
using annotated small compounds LOPAC1280 (Sigma). Our screennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hibitors, olomoucine and roscovitine, as activators of the osteo-
clastogenesis. Our data showed that the inhibition of Cdks and/or
GSK3-β signiﬁcantly upregulates NFATc1 and subsequently en-
hances the formation of functional osteoclasts.2. Material and methods
2.1. Cells and reagents
For the osteoclastogenic culture, RAW264.7 and pNFAT/Luc-
RAW cells were cultured in α-MEM medium containing 10% fetal
bovine serum (FBS), 100 ng/ml soluble RANKL (sRANKL, Peprotech
and Oriental Yeast), 2 mM L-glutamine, 100 units/ml penicillin, and
100 μg/ml streptomycin [10]. For osteoclast formation by using
primary pre-osteoclast cultures, murine bone marrow cells were
obtained from femurs and tibiae of 7-week-old ddY mice (Japan
SLC, Inc.). 4.0105 cells were cultured in α-MEM medium con-
taining 10% fetal bovine serum (FBS), 100 ng/ml sRANKL, 10 ng/ml
M-CSF (Wako, JPN), 2 mM L-glutamine, 100 units/ml penicillin, and
100 μg/ml streptomycin in 24-well plates. Kenpaullone (Sigma),
olomoucine (Sigma), roscovitine (Sigma) are used at a ﬁnal con-
centration of 50 nM. The culture medium in each well was re-
placed by fresh medium containing M-CSF and sRANKL every
2 days. TRAP staining was performed after 5 days of the induction.
2.2. Cell-based screening of the small-compound library
The pNFAT/Luc-RAW cells were used for screen small com-
pounds, LOPAC1280 (Sigma) that contains 1280 compounds of
marketed drugs and pharmaceutically relevant structural deriva-
tives. These compounds are annotated with biological activities
and classiﬁed as follows: cell signaling (9%), phosphorylation (8%),
cell stress (4%), lipids (4%), ion channels (6%), G proteins (3%),
apoptosis/cell cycle (2%), gene regulation (3%), hormone related
(3%), and neuroscience related (58%). The pNFAT/Luc-RAW cells
(5000 cells/well) were plated into 96-well plates in 100 μl of α-
MEM medium with 10% FBS, 2 mM L-glutamine, 100 units/ml pe-
nicillin, and 100 μg/ml streptomycin. The culture medium was
exchanged the next day for fresh medium containing sRANKL
(100 ng/ml), followed by the addition of each compound in the
library to the cells at 10 μM. The luciferase activity of each well
was measured after 24 h using the ONEGlo™ luciferase assay
system (Promega) and a microplate reader (GloMax-Multi Detec-
tion System, Promega).
2.3. TRAP staining
TRAP staining was performed as described previously [11].
Brieﬂy, the cells were ﬁxed with 10% glutaraldehyde for 15 min at
37 °C, and subsequently incubated for 10 min at 37 °C in TRAP
buffer, which consisted of 0.1 M sodium acetate, 0.1 M acetic acid,
10 mg/ml naphthol AS-MX phosphate (Sigma), 0.1% Triton X-100
(Sigma), 0.3 M potassium tartrate (Sigma) and 0.3 mg/ml Fast Red
Violet LB Salt (Sigma). TRAP-positive dark-red cells with more than
three nuclei were counted under light microscope as multi-
nucleated osteoclasts.
2.4. Quantitative real-time PCR
Total RNA was extracted with an RNeasy Mini Kit (QIAGEN,
Hilden, Germany). After DNase I treatment (Ambion, Austin, TX),
cDNAs were synthesized from 2 μg of total RNA using Super
ScriptIII reverse transcriptase (Invitogen, Carlsbad, CA). Quantita-
tive TaqMans real-time PCR analysis for expression of NFATc1 wasperformed using the AB 7300 real-time PCR system (Applied
Biosystems, Foster City, USA). The expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA was used as an internal
control. The TaqMans primer and probe sets used were
Mm00479445_ml (NFATc1) and 4352339E (GAPDH).
2.5. Western blotting
The cells were harvested and lysed in Laemmli sample buffer
[pH6.8; 50 mM Tris–HCl, 2% sodium dodecyl sulfate (SDS), 10%
glycerol, 5% 2-mercaptoethanol] and heated at 95 °C for 5 min.
Equal amounts of whole cell lysates were loaded and resolved via
SDS-PAGE, and subjected to Western blotting analysis by using
anti-NFATc1 monoclonal (7A6, Santa Cruz Biotechnology, Santa
Cruz, CA), anti-cathepsin K polyclonal (ab19027, Abcam), and anti-
β-actin monoclonal antibodies (A5441, Sigma). The signals were
detected with an enhanced chemiluminescence (ECL) plus kit (GE
Healthcare).
2.6. MTT assay
RAW264.7 cells were seeded onto 96-well plates at
50,000 cells/ml in 90 μl α-MEM complete medium. The cultures
were incubated in the presence of 0.1% DMSO, 5 μM kenpaullone,
5 μM olomoucine, or 5 μM roscovitine for 0 (6 h), 1, 2, and 3 days
followed by the addition of 10 μl of 5 mg/ml MTT (3-(4,5-Di-
methylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (Sigma).
After 4 h of incubation, 100 μl of SDS-HCl solution was added and
incubated for 24 h to dissolve the formazan produced by the cells.
Optical densities (OD) were measured at a wavelength of 571 nm.3. Results
3.1. Screen of annotated small compounds modulating osteoclasto-
genesis of RAW264.7
Previously, we constructed RAW264.7 reporter cell line (pNFAT/
Luc-RAW) that stably expresses luciferase under the control of
NFAT-response element activation-dependent promoter [10]. By
using this cell line, we screened the small compound Library of
Pharmacologically Active Compounds (LOPAC1280, Sigma) to
identify drugs which modulate osteoclastogenic pathway. The cells
were treated with sRANKL in the presence of 10 μM of each library
compound or DMSO as a control, and the luciferase activity was
measured after 24 h of incubation (n¼3). Relative luciferase ac-
tivity is deﬁned as log10 ratio of the activity in the presence of
compound vs. the solvent (DMSO). As shown in Fig. 1A, a number
of compounds which signiﬁcantly enhance or inhibit the NFAT-
luciferase activity were identiﬁed. In this study, we focused our
analysis on the activators for osteoclastogenesis. The top 30 acti-
vator candidates for osteoclastogenesis are listed in Table 1. Ken-
pallone (9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-
one), a cyclin-dependent kinases (Cdks)/glycogen synthase kinase
3β (GSK-3β) inhibitor, showed the most signiﬁcant activity in this
screen. As shown in Fig. 1B, the kenpaullone enhanced NFAT-lu-
ciferase activity in a concentration-dependent manner in the
range of which we tested (0–10 μM). Furthermore, to see the effect
of kenpaullone on endogenous NFATc1 mRNA expression levels,
we induced osteoclast formation in RAW264.7 cells with sRANKL
in the presence (5 μM) or absence of kenpaullone for 4 days, and
subsequently analyzed the NFATc1 mRNA levels by real-time RT-
PCR. The mRNA levels were normalized by the levels of control
sample (no sRANKL). As shown in Fig. 1C, the NFATc1 mRNA ex-
pression was signiﬁcantly enhanced in the presence of kenpaul-
lone compared to the cells without the compound.
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Table 1
Top 30 compound hits which upregulate the expression of NFAT-luciferase reporter.
Compounds Targets Mean values
of relative lu-
ciferase activ-
ity (log10)
1 Kenpaullone Cdks/GSK3β 1.012
2 CK2 Inhibitor 2 Casein kinase II 0.858
3 Roscovitine Cdks 0.789
4 Phenamil methanesulfonate Amiloride-sensitive
Naþchannels
0.765
5 3-Deazaadenosine S-adenosyl homo-
cysteine hydrolase
0.716
6 SU 4312 VEGF receptor-2 0.602
7 SB-366791 TRPV1 receptor 0.580
8 PD 98059 MEK 0.539
9 SIB 1757 mGluR5 0.521
10 6-Methyl-2-(phenylethynyl)pyr-
idine hydrochloride
mGluR5 0.476
11 Apigenin Casein kinase II 0.454
12 SIB 1893 mGluR5 0.440
13 1-(5-Isoquinolinylsulfonyl)-2-
methylpiperazine
dihydrochloride
Ser/Thr kinase
inhibitor
0.427
14 Tyrphostin AG 1296 PDGF receptor kinase 0.413
15 H-8 dihydrochloride PKA 0.396
16 BF-170 hydrochloride Tau 0.354
17 9-Cyclopentyladenine Adenylyl cyclase 0.343
18 1,4-PBIT dihydrobromide iNOS 0.333
19 N6-Cyclohexyladenosine Adenosine A1 receptor 0.332
20 Lansoprazole Proton pump 0.322
21 Phenserine Acetylcholinesterase 0.312
22 D-ribofuranosylbenzimidazole RNA polII 0.308
23 1-Phenyl-3-(2-thiazolyl)-2-
thiourea
Dopamine β-
hydroxylase
0.307
24 Riluzole Sodium channels 0.302
25 Ciproxifan hydrochloride H3 receptor 0.301
26 AMG 9810 TRPV1 receptor 0.281
27 Clorgyline hydrochloride Monoamine oxidase 0.274
28 Olomoucine Cdks 0.268
29 Chloro-IB-MECA Adenosine A3 receptor 0.264
30 N-Methyl-beta-carboline-3-
carboxamide
Benzodiazepine
receptor
0.255
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osteoclastogenesis
To determine the effect of kenpaullone on osteoclastogenesis,
RAW264.7 cells were treated with sRANKL in the presence of
kenpaullone. After 4 days of the induction, TRAP staining was
performed. As shown in Fig. 2A, 5 μM kenpaullone signiﬁcantly
increased a number of multinuclear mature osteoclasts compared
to the control. As shown in Table 1, another two Cdk inhibitors,
roscovitine and olomoucine, are in the list of top 30 activator
candidates. Therefore, we also examined the effect of roscovitine
and olomoucine on osteoclastogenesis. As with the kenpaullone,
5 μM of olomoucin and roscovitine enhanced the formation ofFig. 1. Screening of compounds which modulate osteoclastogenesis. (A) Screening
of LOPAC1280 by using cell-based NFAT-luciferase reporter assay. The library com-
pounds in a 96-well format were incubated with pNFAT/Luc-RAW cells at con-
centrations of 10 μM in the presence of 100 ng/ml sRNAKL. Luciferase activity was
measured after 24 h of the treatment. The data represents mean values (n¼3) of
log10 ratio of relative luciferase activity for each compound. Arrows indicate ken-
paullone, roscovitine, and olomoucine. (B) Kenpaullone enhances NFAT promoter.
Promoter activity of NFAT-response element in pNFAT/Luc-RAW cells was mea-
sured by luciferase reporter assay at 24 h after treatment with Kenpaullone. The
results are expressed as the mean values7S.E. (n¼3). (C) Kenpaullone upregulates
NFATc1 mRNA levels in the presence of sRANKL. NFATc1 mRNA levels in the pre-
sence or absence of 5 μM kenpaullone with sRANKL were determined by real-time
RT-PCR and the relative mRNA expression levels were compared. The data re-
present mean values7S.E. with triplicate samples (*Po0.01: ANOVA with Tukey's
multiple comparison test).
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Fig. 2. Kenpaullone, olomoucine, and roscovitine enhance osteoclastogenesis of RAW264.7. (A) The images of TRAP-stained osteoclasts differentiated from RAW264.7 cells
are shown. RAW264.7 cells were induced osteoclastogenic differentiation by 100 ng/ml sRANKL in the presence of 5 μM of kenpaullone, olomoucine, or roscovitine. (B) The
number of generated multinuclear osteoclasts in the presence of various concentrations of the compounds, kenpaullone, olomoucine, and roscovitine, were evaluated after
4 days of the induction. The data represent mean values7S.E. with triplicate samples.
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positive mature osteoclasts with different concentrations of each
compound. All compounds, kenpaullone, olomoucine, and ros-
covitine, remarkably increased the osteoclast differentiation in a
concentration-dependent manner until 5 μM, 1 μM, and 0.25 μM,
respectively (Fig. 2B). To conﬁrm the effect of the compounds on
osteoclastogenesis, we performed the experiment by using pri-
mary pre-osteoclast cultures derived from mice. Since higher
concentration, in the range of μM, of the compounds showed
toxicity to the bone marrow cells (data not shown), we reduced
the concentration of all compounds to 50 nM. After 5 days of os-
teoclastogenic induction by M-CSF and sRANKL with or without
each compound, we observed an increased number of TRAP-po-
sitive mature osteoclasts in the presence of kenpaullone, olo-
moucine, or roscovitine compared to the control (DMSO) (Fig. 3A).
Then, we determined the number of the multinuclear osteoclasts.
Consistent with the result of using RAW264.7 cells (Fig. 2), the all
compounds, kenpullone, olomoucine, and roscovitine, showed
3-fold increase in the number of osteoclast induced from pri-
mary bone marrow cells (Fig. 3B). Taken together, kenpaullone,
olomoucine, and roscovitine signiﬁcantly enhanced the differ-
entiation of both RAW264.7 and primary pre-osteoclast cells
(Figs. 2 and 3), indicating that GSK-3β and/or Cdks negatively
regulate osteoclastogenesis.
3.3. Kenpaullone, olomoucine, and roscovitine increase the levels of
mature cathepsin K in the resultant osteoclasts
To determine whether the resultant mature osteoclasts in the
presence of the compounds are functional or not, we analyzed the
levels of cathpsin K, which is an essential enzyme for bone re-
sorption activity of the mature osteoclast [3,4,12]. Cathepsin K is
processed from premature (approximately 40 kDa) to mature form
(approximately 29 kDa) during osteoclastogenesis. RAW264.7 cellswere induced osteoclastogenic differentiation by RANKL in the
presence or absence of the compounds, kenpuallone, olomoucine,
or roscovotine. After 4 days of the incubation, levels of cathepsin K
in the soluble cell extracts were analyzed by Western blot. As
shown in Fig. 4, the ratio of the levels of mature cathepsin K to
premature cathepsin K in the presence of 5 μM of each compound,
kenpaullone, olomoucine, or roscovitine, was signiﬁcantly higher
compared to the control. This result suggests that the GSK-3β and/
or Cdks inhibitors enhance the resorption activity of the resultant
osteoclasts through promoting osteoclastogenesis.
3.4. Anti-proliferative effect of kenpaullone, olomoucine, and ros-
covitine on RAW264.7 cells
Kenpaullone is known to have an anti-proliferative effect on
MCF-10A cells which are immortalized, non-transformed epithe-
lial cells derived from human ﬁbrocystic tissue [13]. Also, roscov-
itine and olomoucine cause cell-cycle arrest on mouse lympho-
cytic leukemia cells, L1210, and small cell lung cancer cell lines,
NCI-H417 and DMS153 [14]. To investigate the effect of the three
compounds on cell proliferation of RAW264.7 cells, we performed
MTT assay. As shown in Fig. 5, the all three compounds caused
retardation to the cell proliferation: kenpaullone and olomoucine
inhibited to a greater extent than roscovitine. This result suggest
that the decrease in cell cycle progression triggered by GSK-3β
and/or Cdks inhibition could facilitate the direction of the pre-
osteoclast cells toward osteoclastogenic differentiation.4. Discussion
We screened chemical compounds which modulate osteoclas-
togenesis and identiﬁed that Cdks/GSK3-β inhibitor, kenpaullone,
as well as Cdks inhibitors, roscovitine and olomoucine, have
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Fig. 3. Kenpaullone, olomoucine, and roscovitine enhanced osteoclastogenic differentiation of bone marrow-derived pre-osteoclasts. (A) The images of TRAP-stained os-
teoclasts differentiated from murine bone marrow cells are shown. The primary bone marrow cells were induced osteoclastogenic differentiation by 100 ng/ml sRANKL in
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Fig. 4. Kenpaullone, olomoucine, and roscovitine increase the levels of mature
cathepsin K. RAW264.7 cells were incubated with 100 ng/ml sRANKL in the pre-
sence of 5 μM of kenpaullone, olomoucine, or roscovitine. After 4 days of the in-
duction, total cell lysates were subjected to Western blot analysis with anti-ca-
thepsin K and anti-actin antibodies. Premature and mature forms of cathepsisn K
are approximately 40 kDa and 29 kDa, respectively.
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through upregulating NFATc1 expression (Figs. 1 and 2). Then, we
conﬁrmed that the all three inhibitors activates osteoclasogenesis
of primary pre-osteoclasts derived frommurine bone marrow cells
(Fig. 3). Furthermore, the cathepsin K processing during the os-
teoclastogenesis was promoted by the compounds, suggesting that
the bone absorption activity could be also increased (Fig. 4).
Kenpaullone is a well-known Cdk/GSK-3β inhibitor [13,15].
Recent studies have shown that GSK-3β negatively regulatesosteoclastogenesis by directly phosphorylating NFATc1 [16]. The
phosphorylated NFATc1 is no longer able to bind DNA and is
transported to cytoplasm resulting in downregulation of NFATc1-
dependent osteoclast-related genes [17]. It has been shown that
GSK-3β inhibitors such as SB216763, SB415286, and kenpaullone
remarkably enhance osteoclastogenesis [18]. We also conﬁrmed
that GSK-3β inhibitors, SB415286 and CHIR99021, signiﬁcantly
enhanced the differentiation of RAW264.7 (data not shown). These
results indicate that the GSK-3β inhibitors promote osteocal-
stogenesis. Among them, kenpaullone has one of the strongest
inhibitory function on GSK-3β (IC50¼0.023 μM) [15]. Kenpaullone
also has a potent inhibitory effect on Cdks with the following IC50
values: Cdk1/cyclin B (IC50¼0.4 μM), Cdk2/cyclin A (IC50
¼0.68 μM), Cdk5/p35 (IC50¼0.85 μM) [13]. Intriguingly, our che-
mical screen identiﬁed Cdks inhibitors, olomoucine and roscov-
itine, as activators of osteoclastogenesis. Olomoucine inhibits
Cdk2/cyclin A at IC50¼7 μM and Cdk5/P35 at IC50¼3 μM [19],
while roscovitine has more potency than olomoucine: Cdk2/cyclin
A (IC50¼0.7 μM) and Cdk5/P35 (IC50¼0.16 μM) [20]. Note that
roscovitine is unable to inhibit GSK-3β [15]. Thus, olomoucine and
roscovitine could enhance osteoclastogenesis by inhibiting Cdks
but not GSK-3β while kenpaullone promotes osteoclast differ-
entiation by inhibiting both Cdks and GSK-3β. Hence, our data
indicates that the both Cdks and GSK-3β negatively regulate
osteoclastogenesis.
It has been suggested that cell proliferation and osteoclast
differentiation are regulated by cyclin, Cdk, and Cdk inhibitor
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Fig. 5. Kenpaullone, olomoucine, and roscovitine affect cell proliferation of
RAW264.7. RAW264.7 cells were seeded onto 96-well plates and cultured in the
presence of 0.1% DMSO (▲), 5 μM kenpaullone (●),5 μM olomoucine (■), or 5 μM
roscovitine (♦) for 0 (6 h), 1, 2, and 3 days followed by the addition of MTT. Optical
densities (OD) were measured at a wavelength of 571 nm. The data represent mean
values7S.D. with triplicate samples (*Po0.01: ANOVA with Tukey's multiple
comparison test).
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the expression of cell cycle regulatory proteins. Cyclin D2 and D3,
positive regulators of G1/S transition, as well as Cdk6 are all up-
regulated whereas Cdk2 levels are repressed, resulting in S phase
delay [21]. Also, Cdk inhibitor proteins, p21CIP1 and p27KIP1 are
signiﬁcantly upregulated at initial stage of the osteoclastogenesis
and decreased at 2 days post-RANKL induction in mouse bone
marrow-derived macrophages [22], indicating that the cell cycle
stalling in osteoclast precursors is a prerequisite for differentiation
into osteoclasts. Another study identiﬁed a cell cycle-arrested
quiescent osteoclast precursors (QuOPs) in vivo which are main-
tained as committed osteoclast precursors by downregulating
Cdks and cyclins and upregulating p27KIP1 [23]. We also observed
that the kenpaullone, olomoucine, and roscovitine stall the cell
proliferation of the pre-osteoclast cells (Fig. 5). These results in-
dicate that the cell cycle regulatory system plays an important role
in osteoclastogenesis pathway, although it remains unclear the
molecular mechanism. Further mechanistic studies will be re-
quired to understand the physiological role of the cell cycle reg-
ulators in osteoclast differentiation and bone remodeling.Acknowledgments
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